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Abstract
AIM: To study the response to infliximab in pediatric 
inflammatory bowel disease (IBD), as reflected in fecal 
calprotectin levels. 
METHODS: Thirty-six pediatric patients with IBD [23 
Crohn’s disease (CD), 13 ulcerative colitis (UC); median 
age 14 years] were treated with infliximab. Fecal cal-
protectin was measured at baseline, and 2 and 6 wk 
after therapy, and compared to blood inflammatory 
markers. Maintenance medication was unaltered until 
the third infusion but glucocorticoids were tapered off 
if the patient was doing well. 
RESULTS: At introduction of infliximab, median fecal 
calprotectin level was 1150 µg/g (range 54-6032 µg/g). 
By week 2, the fecal calprotectin level had declined to a 
median 261 µg/g (P  < 0.001). In 37% of the patients, 
fecal calprotectin was normal (< 100 µg/g) at 2 wk. By 
week 6, there was no additional improvement in the fe-
cal calprotectin level (median 345 µg/g). In 22% of the 
patients, fecal calprotectin levels increased by week 6 to 
pretreatment levels or above, suggesting no response (or 
a loss of early response). Thus, in CD, the proportion 
of non-responsive patients by week 6 seemed lower, 
because only 9% showed no improvement in their fecal 
calprotectin level when compared to the respective fig-
ure of 46% of the UC patients (P < 0.05). 
CONCLUSION: When treated with infliximab, fecal 
calprotectin levels reflecting intestinal inflammation 
normalized rapidly in one third of pediatric patients sug-
gesting complete mucosal healing. 
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
The recent development of  easily applicable fecal sur-
rogate markers for intestinal inflammation has provided 
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new means for objective assessment of  disease activ-
ity and treatment response in chronic inflammatory 
bowel disease (IBD), a disease becoming more prevalent 
among children[1]. This is especially important in pediat-
ric patients with limited possibility for follow-up endos-
copy due to invasiveness. The fecal levels of  neutrophil-
derived markers, such as fecal calprotectin or lactoferrin, 
reflect the mucosal influx of  inflammatory cells in the 
intestine, thus associating with the presence of  active 
inflammation. In IBD, fecal calprotectin levels relate to 
the findings in endoscopy but also with the grade of  
histological inflammation[1-4]. When compared to clinical 
scores and serum inflammatory markers, fecal calprotec-
tin is the most accurate tool to detect the presence of  ac-
tive mucosal inflammation in the colon[4-6]. The negative 
predictive value for the presence of  active inflammation 
is high (87%)[4]. In children, it has been shown that the 
level of  fecal calprotectin[2,3,7,8] or lactoferrin[6,9] may guide 
the need for endoscopy.
The data on fecal markers during therapy of  IBD are 
sparse. We showed recently that during glucocorticoid 
therapy in pediatric patients, fecal calprotectin levels 
rarely declined below the limit of  a raised value, suggest-
ing ongoing mucosal inflammation. However, in those 
clinically responding to therapy, fecal calprotectin values 
fell markedly during the first month of  therapy[10]. In 
children presenting with clinically quiescent IBD, only 
one third of  the patients have fecal calprotectin levels 
below the upper normal limit, whereas the others have 
raised values, although not reporting subjective symp-
toms[11]. In adults, fecal calprotectin values are associated 
with mucosal healing in Crohn’s disease (CD) patients 
who respond to therapy with tumor necrosis factor 
(TNF)-α antagonists or other IBD medication[12,13]. In 
a pilot study by Buderus et al[14], the levels of  fecal lac-
toferrin were measured in five children on infliximab 
therapy, who showed a decline after the first infusion in 
each case. The pattern of  fecal calprotectin levels during 
introduction of  TNF-α antagonist therapy in children 
has not yet been described.
In pediatric patients, TNF-α antagonists have emerged 
for therapy of  severe IBD that does not respond to con-
ventional treatment[15-17]. Fecal calprotectin provides a 
non-invasive means to assess the presence of  intestinal 
inflammation, therefore, we conducted a prospective 
study in pediatric patients treated with TNF-α antago-
nist infliximab. Our aim was to study the pattern of  fecal 
calprotectin concentrations during the early phase of  
therapy.
MATERIALS AND METHODS
Study population
We prospectively studied 36 children (median age 14 years, 
range 5.6-17.6 years; 20 boys 20, 16 girls) diagnosed 
with IBD according to the Lennard-Jones criteria[18], and 
consecutively introduced to therapy with infliximab. In 
two cases, the diagnosis of  CD was based on extensive 
aphthous ulceration visualized by wireless capsule en-
doscopy. All patients had moderate to severe disease that 
did not respond to treatment with 5-aminosalicylic acid 
(5-ASA), immunosuppressants or glucocorticoids. In 
four cases, infliximab was introduced shortly after a diag-
nosis of  extensive small bowel disease. In three patients, 
the indication for anti-TNF-α agent was fistulating dis-
ease, and in all the others, poor response to maintenance 
medication or steroid dependency. The study group 
comprised 23 pediatric patients with CD, and 13 with 
ulcerative colitis (UC). The background data, disease dis-
tribution, and medication of  the patients are shown in 
Table 1. Fourteen patients underwent ileocolonoscopy, 
seven underwent wireless capsule endoscopy, and seven 
magnetic resonance imaging enterography within 1 m 
prior to the introduction of  infliximab therapy, confirm-
ing active disease. 
TNF-α antagonist infliximab (Remicade®) was sche-
duled at 5 mg/kg at weeks 0, 2 and 6. All infusions were 
administered at the Hospital for Children and Adoles-
cents, Helsinki University, Finland during February 2008 
to December 2010. The maintenance medication was 
unaltered until week 6, but if  the patient improved clini-
cally, glucocorticoids were tapered off. At each visit, the 
patients provided a stool sample for fecal calprotectin 
measurement and a blood sample for measurement of  in-
flammatory marker erythrocyte sedimentation rate (ESR), 
and hemoglobin. Fecal calprotectin was measured in the 
routine clinical laboratory by a quantitative enzyme immu-
noassay (PhiCal Test, Calpro AS, Oslo, Norway; NovaTec 
Immunodiagnostica, Dietzenbach, GmBH, Germany) and 
the values quoted as normal were < 100 µg/g stool[10,19]. 
The clinical activity of  the disease was assessed by physi-
cians global assessment (PGA) score from 1 to 3[20].
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  Variable     Result
  Age median (range) 14 (5.6-17) yr
  Sex 20 boys, 16 girls
  Diagnosis
  CD         23
    Ileitis           8
    Ileocolitis           8
    Colitis           7
  UC         13
    Left-sided colitis           4
    Pancolitis           9
  Maintenance medication at baseline
  5-ASA         10
  5-ASA + azathioprine/6-MP         12
  Azathioprine/6-MP           7
  None           7
  Prednisolone/budesonide at baseline         19
  Disease duration (median, range) 2.1 (0.4-7.6) yr
Table 1  Background data of 36 pediatric patients with in-
flammatory bowel disease treated with infliximab
CD: Crohn�s disease; UC: Ulcerative colitis; 5-ASA: 5-aminosalicylic acid;        
6-MP: 6-mercaptopurine.
Ethical considerations
The ethics committee of  Helsinki University Central 
Hospital approved the study protocol. The families at-
tending the study signed an informed consent form. 
Statistical analysis
Spearman non-parametric correlation test, Kruskal-Wallis 
test, Mann-Whitney U test, and Fisher’s exact test were 
used. The level of  statistical significance was P < 0.05. 
The values are presented as median and range.
RESULTS
Fecal calprotectin was high at the introduction of  inflix-
imab therapy, with a median value of  1150 µg/g (range: 
54-6032 µg/g). Two patients had fecal calprotectin < 
100 µg/g (reference limit for a raised value), and their 
indication for treatment was steroid-dependent colitis. 
By week 2, the median level of  fecal calprotectin level 
had declined to 261 µg/g (Figure 1; P < 0.001, Mann-
Whitney U test). In 11 of  30 (37%) patients, fecal cal-
protectin was below the reference limit (100 µg/g) by 
week 2. By week 6, there was no additional improvement 
in the median fecal calprotectin level (345 µg/g, range: 
5-5253 µg/g, Figure 1). The individual variation of  fecal 
calprotectin levels is shown in Figure 2. 
Disease extension or diagnosis did not relate to fe-
cal calprotectin levels or to treatment response (data 
not shown). Fecal calprotectin decreased in 21 of  22 
(95%) of  the CD patients, with a raised value during the 
introduction phase, but in one case, the response was 
temporary. By week 6, there was no response in two 
cases when compared to baseline. One patient with CD 
presented with low fecal calprotectin levels throughout 
the study period. In this particular case, the indication 
for treatment was steroid dependency and steroids were 
tapered off  during induction. Thus, the effect of  inflix-
imab therapy on fecal calprotectin could not be assessed, 
and she was not included in the analysis. Of  the UC 
patients with increased fecal calprotectin at baseline, the 
level decreased in 10 of  12 (83%) patients, but increased 
to pretreatment levels or above by week 6 in three of  
10 (30%) children. Of  the two children with no initial 
decline in fecal calprotectin level, there was no clinical 
response and the level stayed constantly high (> 1600 µg/g) 
or increased more than 10-fold within 6 wk. The child 
with steroid-dependent UC and low fecal calprotectin at 
the start of  this therapy (high disease activity confirmed 
in colonoscopy 1.5 mo earlier) showed mild elevation 
in the level (up to 120 µg/g). Thus, by week 6, fecal cal-
protectin level suggested a response in 20 of  22 (91%) 
of  the CD patients and in seven of  13 (54%) of  the UC 
patients (P < 0.05, Fisher’s exact two-tailed test), corre-
sponding to a figure of  22% of  non-responsive patients 
in total.
Blood inflammatory marker ESR decreased from a 
median value of  20 mm/h (range: 2-46 mm/h) at base-
line to 9 mm/h (range: 2-34 mm/h, P < 0.05, Mann-
Whitney U test) at 2 wk. At baseline, 19 of  31 patients 
(61%) had elevated ESR. By week 2, the respective figure 
was 28% (9/32). Median PGA score was 2 at baseline 
(range: 1-3), and by week 2 and 6, the score was 1 (range: 
1-3, P < 0.001); by week 6, the majority of  patients (33/36) 
presented with a score of  1. For hemoglobin levels, there 
was no significant increase in the median values [118 g/L 
(range: 95-152 g/L) at baseline and 124 g/L at 2 wk (range: 
80-147 g/L)]. Glucocorticoids were tapered off  in 10/19 
patients during the induction phase. 
DISCUSSION
Therapy with TNF-α antagonists has emerged in pedi-
atric patients suffering from moderate to severe CD[21,22], 
but recently, a therapeutic response has also been re-
ported in severe UC[16,23]. These therapies are effective 
but at present have high costs and carry a risk for the 
development of  severe adverse effects, which possibly 
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Figure 1  Fecal calprotectin levels at baseline, and 2 and 6 wk after intro-
duction of infliximab therapy in children with Crohn’s disease or ulcerative 
colitis. The decline in levels between baseline and week 2 was statistically 
significant (P < 0.001). CD: Crohn’s disease; UC: Ulcerative colitis.
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Figure 2  Fecal calprotectin levels at baseline, and 2 and 6 wk after intro-
duction of infliximab therapy showing the individual variation in children 
with inflammatory bowel disease.
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hampers their clinical use[24,25]. Thus, it is of  key impor-
tance to target the therapy on those who show a positive 
response and to discontinue administration of  TNF-α 
antagonists if  the patient is a non-responder[25]. In keep-
ing with this, surrogate markers for the presence of  
intestinal inflammation such as fecal calprotectin[13,26] are 
promising and non-invasive means for the assessment of  
disease activity in IBD. There have only been a few stud-
ies on fecal calprotectin related to therapeutic response 
in IBD. Previously, we have assessed the pattern of  fecal 
calprotectin in acute pediatric IBD from the start of  glu-
cocorticoid therapy until their discontinuation[10], and in 
adults during the first 12 wk of  TNF-α antagonist ther-
apy[12]. Here, we showed the pattern of  fecal calprotectin 
in pediatric IBD during the induction phase of  TNF-α 
antagonist therapy, demonstrating a rapid decline in fe-
cal calprotectin levels within the first weeks of  induction 
in the majority of  pediatric IBD patients, suggesting an 
early response.  
By week 2 after introduction of  infliximab, the medi-
an level of  fecal calprotectin had declined by 77% from 
baseline. Expectedly, this rapid decrease in fecal calpro-
tectin in children paralleled the pattern seen in adults 
after introduction of  TNF-α antagonist treatment. In 
a previous study in adults, endoscopy confirmed remis-
sion in 30% of  CD patients when assessed at 3 mo[12]. In 
the present study, in one third of  the children, the fecal 
calprotectin levels had declined to normal - suggest-
ing remission - by week 2 after the start of  infliximab 
therapy. Unexpectedly, there were only a few cases that 
showed normalization of  fecal calprotectin by week 6, 
thus, the 2-wk result equaled the proportion of  children 
with suggested mucosal healing - the target of  IBD 
therapy[27] - and remission during the induction phase. 
The finding of  an excellent therapeutic response in one 
third of  the patients is comparable to our previous find-
ings in children with acute IBD treated with glucocorti-
coids (showing a normalization of  fecal calprotectin in 
27% of  patients[10]), and in adults treated with TNF-α 
antagonist therapy[12] (see above). In two thirds of  the 
patients, fecal calprotectin did not normalize, suggesting 
incomplete mucosal healing during the induction phase 
of  infliximab therapy. It is important to note that the fe-
cal calprotectin level that is considered as a satisfactory 
therapeutic response remains undecided. Furthermore, 
the long-term treatment outcome in pediatric patients 
related to fecal calprotectin levels warrants further stud-
ies. In adult patients, mucosal healing predicts a better 
long-term outcome[28].
Although primary response to TNF-α antagonist 
therapy is excellent in children, covering 80%-90% of  
patients with CD, the therapeutic response according to 
clinical disease activity may deteriorate during the first 
year of  therapy in a considerable proportion of  children. 
It has been estimated that 34%-49% of  initial respond-
ers need dose escalation or more intense therapy during 
the first year of  infliximab therapy[15,22]. For infliximab 
therapy in adults, rates of  dose intensification ranging 
from 31% to 36% at 12 mo are comparable to those in 
pediatric patients[29,30]. Here, the primary response was 
possibly lost already during the introduction phase in > 
10% of  the patients, as reflected in the fecal calprotectin 
levels. In these particular children, PGA did not decrease 
either. However, clinical activity indices have less correla-
tion to the presence of  mucosal inflammation than fecal 
neutrophil biomarkers, as shown in adult CD patients[31]. 
Thus, reliance solely on clinical assessment is insuf-
ficient, and constantly high fecal calprotectin concen-
tration during therapy warrants endoscopic evaluation 
also in children. It should be noted that increased fecal 
calprotectin level does not discriminate between disease 
relapse and intestinal infection[32].
Blood hemoglobin levels did not significantly alter 
during the induction phase, but the median ESR de-
creased during the induction phase by week 2. However, 
39% of  the patients had normal ESR at baseline, and 
in these patients, ESR is not applicable for assessment 
of  therapeutic response. In children with IBD, serum 
C-reactive protein (CRP) is seldom increased, and dis-
appointingly, the measurement of  high-sensitivity CRP 
does not bring additional benefit for the assessment of  
disease activity[33]. Thus, CRP levels were not measured 
systematically in the present study. It has also been shown 
in adult IBD that CRP is a poor marker in mild to mod-
erate disease[34], and performance of  fecal calprotectin is 
significantly better[6].
As in many pediatric studies, one of  the major limi-
tations of  the present study was the small size of  the 
study group. The majority of  the patients had CD but 
as there were only 13 cases of  UC, comparisons related 
to diagnosis of  IBD should be interpreted with caution. 
Most patients with CD presented with ileocolitis, and 
the numbers of  patients with terminal ileal disease or 
CD colitis were too small to allow proper comparisons 
related to therapeutic response to infliximab therapy.  
In conclusion, fecal surrogate markers may provide 
objective and non-invasive means to determine the re-
sponse to infliximab in individual patients early in treat-
ment. Also, fecal calprotectin is more reliable than clini-
cal activity indices or blood-borne markers of  inflamma-
tion. It may be possible to identify responding patients 
by a rapid drop in fecal calprotectin levels, which can be 
seen already at week 2. By week 6, little improvement is 
evident and some patients even appear to lose their ther-
apeutic response. Based on our results, fecal calprotectin 
is a promising marker for evaluating patient response to 
TNF-α antagonist therapy and may offer a tool for iden-
tifying responding patients at an early stage, for more 
efficient targeting of  treatment.
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Background 
In pediatric patients, tumor necrosis factor (TNF)-α antagonists have emerged 
for therapy of severe inflammatory bowel disease (IBD), in patients who do not 
respond to conventional treatment. In children, endoscopy is an invasive proce-
dure, which limits its use in follow-up. Fecal calprotectin is a surrogate marker 
for the presence of intestinal inflammation and thus provides a non-invasive 
means to assess disease activity in children.
Research frontiers 
The recent development of easily applicable fecal surrogate markers for intesti-
nal inflammation has provided new means for objective assessment of disease 
activity and treatment response in chronic IBD, a disease becoming more 
prevalent among children. When compared to clinical scores and serum inflam-
matory markers, fecal calprotectin is the most accurate tool to detect the pres-
ence of active mucosal inflammation in the intestine, and it is easily applicable 
to pediatric clinical practice.
Innovations and breakthroughs 
This is believed to be the first pediatric study to follow fecal calprotectin levels 
during the induction phase of therapy with TNF-α antagonist agent infliximab. 
The study showed that, in one third of pediatric patients, fecal calprotectin level 
normalized by week 2. However, in two thirds of the patients, fecal calprotectin 
levels stayed elevated by week 6, suggesting incomplete mucosal healing. 
Applications 
Based on the results, fecal calprotectin is a promising marker for objective eval-
uation of patient response to TNF-α antagonist therapy and may offer a tool for 
identifying responding patients at an early stage, for more efficient targeting of 
treatment. The long-term treatment outcome in pediatric patients related to fe-
cal calprotectin levels after induction therapy warrants further study.
Terminology
IBD consists of Crohn’s disease, ulcerative colitis and indeterminate colitis, and 
is a chronic illness that affects the intestines, with a partly TNF-α-driven inflam-
mation that is effectively abated by TNF-α antagonists such as infliximab. Fecal 
calprotectin is a neutrophil-derived marker of inflammation that is present in the 
stools, and is a reliable surrogate for endoscopic evaluation of disease activity. 
Peer review
The authors prospectively evaluated the therapeutic response in pediatric IBD 
patients during introduction to infliximab reflected in fecal calprotectin levels. It 
is a relevant study and the paper is well presented.
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